{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:36:52Z","timestamp":1781829412077,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"DOI":"10.7759\/cureus.56182","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T20:14:43Z","timestamp":1710447283000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Biologics in the Treatment of Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"David","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Rubtsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myat Myat","family":"Khaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen TH","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017, 67:1298-323. 10.1016\/j.jhep.2017.07.022","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.8.5.435","article-title":"Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis","volume":"8","author":"Thorpe ME","year":"1967","unstructured":"Thorpe ME, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut. 1967, 8:435-48. 10.1136\/gut.8.5.435","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis","volume":"21","author":"de Vries AB","year":"2015","unstructured":"de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015, 21:1956-71. 10.3748\/wjg.v21.i6.1956","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709025107","article-title":"Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease","volume":"32","author":"Rasmussen HH","year":"1997","unstructured":"Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol. 1997, 32:604-10. 10.3109\/00365529709025107","journal-title":"Scand J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott C","year":"2013","unstructured":"Ott C, Sch\u00f6lmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013, 10:585-95. 10.1038\/nrgastro.2013.117","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i46.17463","article-title":"Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients","volume":"20","author":"Zippi M","year":"2014","unstructured":"Zippi M, Corrado C, Pica R, et al.. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014, 20:17463-7. 10.3748\/wjg.v20.i46.17463","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.1.131","article-title":"Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis","volume":"49","author":"Bo X","year":"2001","unstructured":"Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001, 49:131-41. 10.1136\/gut.49.1.131","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2505","article-title":"Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease","volume":"357","author":"Cohen BL","year":"2017","unstructured":"Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017, 357:j2505. 10.1136\/bmj.j2505","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson R","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS, et al.. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005, 129:1464-72. 10.1053\/j.gastro.2005.08.017","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos CK","year":"2011","unstructured":"Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011, 34:901-10. 10.1111\/j.1365-2036.2011.04822.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90610-6","article-title":"A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis","volume":"106","author":"Knox TA","year":"1994","unstructured":"Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994, 106:494-9. 10.1016\/0016-5085(94)90610-6","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01441.x","article-title":"Tacrolimus for the treatment of primary sclerosing cholangitis","volume":"27","author":"Talwalkar JA","year":"2007","unstructured":"Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 2007, 27:451-3. 10.1111\/j.1478-3231.2007.01441.x","journal-title":"Liver Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02267.x","article-title":"Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group","volume":"95","author":"van Hoogstraten HJ","year":"2000","unstructured":"van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al.. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol. 2000, 95:2015-22. 10.1111\/j.1572-0241.2000.02267.x","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17123","article-title":"Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease","volume":"56","author":"Biron A","year":"2022","unstructured":"Biron A, Beaugerie L, Chazouill\u00e8res O, Kirchgesner J. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022, 56:857-68. 10.1111\/apt.17123","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron B","year":"2019","unstructured":"Caron B, Peyrin-Biroulet L, Pariente B, et al.. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study. J Crohns Colitis. 2019, 13:1239-47. 10.1093\/ecco-jcc\/jjz088","journal-title":"J Crohns Colitis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen B","year":"2018","unstructured":"Christensen B, Micic D, Gibson PR, et al.. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018, 47:753-62. 10.1111\/apt.14525","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000596","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options","volume":"28","author":"Franceschet I","year":"2016","unstructured":"Franceschet I, Cazzagon N, Del Ross T, D'Inc\u00e0 R, Buja A, Floreani A. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. Eur J Gastroenterol Hepatol. 2016, 28:508-13. 10.1097\/MEG.0000000000000596","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin CR","year":"2020","unstructured":"Hedin CR, Sado G, Ndegwa N, et al.. Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2020, 18:2295-304.e2. 10.1016\/j.cgh.2020.02.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes DW","year":"2008","unstructured":"Hommes DW, Erkelens W, Ponsioen C, et al.. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008, 42:522-6. 10.1097\/MCG.0b013e3181662426","journal-title":"J Clin Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch KD","year":"2020","unstructured":"Lynch KD, Chapman RW, Keshav S, et al.. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020, 18:179-87.e6. 10.1016\/j.cgh.2019.05.013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse CS","year":"2018","unstructured":"Tse CS, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018, 48:190-5. 10.1111\/apt.14829","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","volume":"21","author":"Schregel I","year":"2023","unstructured":"Schregel I, Ramos GP, Ioannou S, Culver E, F\u00e4rkkil\u00e4 M, Schramm C. Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study. Clin Gastroenterol Hepatol. 2023, 21:3448-50.e3. 10.1016\/j.cgh.2023.01.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo D","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018, 27:1785-805. 10.1177\/0962280216669183","journal-title":"Stat Methods Med Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/09622802231172043","article-title":"Detecting the skewness of data from the five-number summary and its application in meta-analysis","volume":"32","author":"Shi J","year":"2023","unstructured":"Shi J, Luo D, Wan X, Liu Y, Liu J, Bian Z, Tong T. Detecting the skewness of data from the five-number summary and its application in meta-analysis. Stat Methods Med Res. 2023, 32:1338-60. 10.1177\/09622802231172043","journal-title":"Stat Methods Med Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi J","year":"2020","unstructured":"Shi J, Luo D, Weng H, Zeng XT, Lin L, Chu H, Tong T. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020, 11:641-54. 10.1002\/jrsm.1429","journal-title":"Res Synth Methods"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014, 14:135. 10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi PJ","year":"2020","unstructured":"Trivedi PJ, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J, Hirschfield GM. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020, 159:915-28. 10.1053\/j.gastro.2020.05.049","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(66)90339-4","article-title":"Primary sclerosing cholangitis. A study of forty-two cases","volume":"111","author":"Warren KW","year":"1966","unstructured":"Warren KW, Athanassiades S, Monge JI. Primary sclerosing cholangitis. A study of forty-two cases. Am J Surg. 1966, 111:23-38. 10.1016\/0002-9610(66)90339-4","journal-title":"Am J Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weism\u00fcller TJ","year":"2017","unstructured":"Weism\u00fcller TJ, Trivedi PJ, Bergquist A, et al.. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017, 152:1975-84.e8. 10.1053\/j.gastro.2017.02.038","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al.. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023, 388:1966-80. 10.1056\/NEJMoa2212728","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah A","year":"2019","unstructured":"Shah A, Crawford D, Burger D, et al.. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis. 2019, 39:432-41. 10.1055\/s-0039-1688501","journal-title":"Semin Liver Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238617-efficacy-of-biologics-in-the-treatment-of-primary-sclerosing-cholangitis-associated-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T20:14:46Z","timestamp":1710447286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238617-efficacy-of-biologics-in-the-treatment-of-primary-sclerosing-cholangitis-associated-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.56182","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}